Endocrine Health: Hormones, Bones, and Fertility
At a Glance
Boucher-Neuhäuser syndrome can disrupt reproductive hormones, causing delayed puberty, reduced fertility, and risk of weak bones. Care may include individualized hormone replacement, regular bone-density scans, bone-health support, and specialist fertility counseling.
Because Boucher-Neuhäuser syndrome (BNS) affects the brain’s ability to signal the reproductive system, managing your hormone levels is a lifelong part of your care. This is not just about puberty or fertility; it is a critical part of keeping your bones strong and your body healthy [1][2].
Understanding Hypogonadotropic Hypogonadism
In a typical body, the pituitary gland or hypothalamus at the base of the brain acts like a commander, sending out “messenger” hormones called LH and FSH to tell the body to produce testosterone or estrogen. In BNS, this communication line is broken. The “commander” fails to send the signal, leading to a state of hypogonadotropic hypogonadism [1][2].
- In Adolescence: This usually appears as delayed puberty. You or your child may not experience the typical growth spurts, voice changes, or physical development expected during the teenage years [1][3].
- In Adulthood: Without treatment, low hormone levels can lead to persistent fatigue, low sex drive, and a higher risk for metabolic issues like weight gain or high cholesterol [4]. (Be aware that severe fatigue, sleep problems, anxiety, and depression can also have their own neurological or social causes; you should screen for these directly rather than assuming hormone replacement will resolve them entirely.)
Hormone Replacement Therapy (HRT)
The standard of care for BNS involves individualized Hormone Replacement Therapy (HRT). The goal is to provide the body with the hormones it cannot make on its own [5].
- For People with Testes: Treatment typically involves testosterone, which can be given as a skin gel, a patch, or an injection [6][7]. If started in the teens, gradual dose escalation is used to mimic puberty and avoid overly rapid bone-age advancement while providing needed sex-steroid exposure; sex steroids also eventually contribute to growth-plate closure, so treatment is carefully managed [8]. Note: Testosterone supports puberty and bone health, but it does not induce sperm production and may actually suppress spermatogenesis when fertility is desired.
- For People with Ovaries/a Uterus: Treatment begins with estrogen to support breast development and uterine health. For people with a uterus, a progestogen (like progesterone) is generally needed after adequate estrogen exposure to protect the lining of the uterus [1][9]. Discuss contraception and pregnancy planning with your endocrinologist, as treatments depend on your individual goals.
The Critical Link to Bone Health
One of the most significant risks in BNS is secondary osteoporosis (weak, brittle bones caused by an underlying medical condition). Sex hormones are essential for building and maintaining bone density [2][5].
- The Silent Risk: Without enough estrogen or testosterone, bones can become thin and prone to fractures. This is particularly dangerous for people with BNS because the ataxia (balance issues) already increases the risk of falling [2].
- A Noteworthy Warning: Research has shown that some people with BNS develop osteoporosis even when they are receiving adequate hormone replacement [2]. This means that simply taking your HRT is not enough; you must also have regular DEXA scans (bone density X-rays). The timing and repeat intervals should be individualized based on your age, nutrition, and fracture history. Adolescents require pediatric interpretation with Z-scores. You should also maintain adequate dietary calcium and Vitamin D with laboratory-guided supplementation, alongside safe weight-bearing activity [5].
Fertility and the Future
Spontaneous fertility is uncommon in complete hypogonadotropic hypogonadism but can occur in partial disease [10][11]. If you desire biological children, consult a reproductive endocrinologist for individualized expectations.
- Fertility Induction: To try for a pregnancy, a specialist may prescribe injections of hCG and hMG (or FSH), or pulsatile GnRH. These medications act as the “missing signals” to stimulate the production of sperm or the release of eggs [12][13].
- Genetic Counseling: Because PNPLA6 is autosomal recessive, partner carrier testing and reproductive counseling are highly recommended. Response to fertility induction varies widely depending on anatomy and reserve, and treatment options such as IVF may be indicated for some individuals [10][11].
Broader Pituitary Health
While the primary issue in BNS is the reproductive hormones, the PNPLA6 mutation can sometimes affect other parts of the pituitary system [14]. Your endocrinologist may occasionally evaluate other pituitary axes based on your symptoms, such as checking your central thyroid function (interpreting free T4 with TSH) and using IGF-1 as a screening measure for growth hormone (which may require follow-up stimulation testing) to ensure your entire endocrine system is working as it should [14][15].
Common questions in this guide
What hormone replacement is used for Boucher-Neuhäuser syndrome?
Can testosterone treatment improve fertility in Boucher-Neuhäuser syndrome?
Why do people with BNS need DEXA bone scans?
Is natural fertility possible with Boucher-Neuhäuser syndrome?
Can Boucher-Neuhäuser syndrome affect thyroid or growth hormone function?
How is delayed puberty managed in Boucher-Neuhäuser syndrome?
Should families consider genetic counseling for Boucher-Neuhäuser syndrome?
Get notified when new evidence is published on Ataxia-hypogonadism-choroidal dystrophy syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (15)
- 1
Identification of Novel Compound Heterozygous Variants of the PNPLA6 Gene in Boucher-Neuhäuser Syndrome.
He J, Liu X, Liu L, et al.
Frontiers in genetics 2022; (13()):810537 doi:10.3389/fgene.2022.810537.
PMID: 35198007 - 2
Boucher Neuhäuser Syndrome - A rare cause of inherited hypogonadotropic hypogonadism. A case of two adult siblings with two novel mutations in PNPLA6.
Langdahl JH, Frederiksen AL, Nguyen N, et al.
European journal of medical genetics 2017; (60(2)):105-109 doi:10.1016/j.ejmg.2016.11.003.
PMID: 27866050 - 3
PNPLA6-related syndromic retinal dystrophy: A genetically confirmed case of Boucher-Neuhauser syndrome from the Kingdom of Bahrain.
Almohsen MA, Alasal AE, Jamal HF
Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society 2026; (40(3)):314-317 doi:10.4103/sjopt.sjopt_223_24.
PMID: 42757075 - 4
Metabolic Disorders and Male Hypogonadotropic Hypogonadism.
Pivonello R, Menafra D, Riccio E, et al.
Frontiers in endocrinology 2019; (10()):345 doi:10.3389/fendo.2019.00345.
PMID: 31402895 - 5
Management of Hypopituitarism.
Alexandraki KI, Grossman A
Journal of clinical medicine 2019; (8(12)) doi:10.3390/jcm8122153.
PMID: 31817511 - 6
Novel PNPLA6 Variants: Hypogonadotropic Hypogonadism, Pituitary Hypoplasia, Anosmia, and Cerebellar Atrophy in Siblings.
Hussain MA, Kumar V, Chapla A, et al.
JCEM case reports 2026; (4(1)):luaf286 doi:10.1210/jcemcr/luaf286.
PMID: 41356532 - 7
Switch to restoration therapy in a testosterone treated central hypogonadism with erythrocytosis.
Cangiano B, Cacciatore C, Persani L, Bonomi M
Endocrinology, diabetes & metabolism case reports 2017; (2017()) doi:10.1530/EDM-17-0055.
PMID: 28721216 - 8
Treatment situation of male hypogonadotropic hypogonadism in pediatrics and proposal of testosterone and gonadotropins replacement therapy protocols.
Sato N, Hasegawa T, Hasegawa Y, et al.
Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology 2015; (24(2)):37-49 doi:10.1297/cpe.24.37.
PMID: 26019400 - 9
A Case of Male Osteoporosis: A 37-Year-Old Man with Multiple Vertebral Compression Fractures.
Radi S, Karaplis AC
Case reports in endocrinology 2017; (2017()):6328524 doi:10.1155/2017/6328524.
PMID: 28791186 - 10
Fertility Outcomes in Men with Nonobstructive Azoospermia Due to Hypogonadotropic Hypogonadism After Gonadotropin Therapy.
Zachariou A, Zikopoulos A, Markou E, et al.
Journal of clinical medicine 2026; (15(3)) doi:10.3390/jcm15031204.
PMID: 41682884 - 11
The Reproductive Outcome of Women with Hypogonadotropic Hypogonadism in IVF.
Zhang CM, Zhang H, Yang R, et al.
Frontiers in endocrinology 2022; (13()):850126 doi:10.3389/fendo.2022.850126.
PMID: 35733765 - 12
Evaluating Sperm Recovery Time and Efficacy of Monotherapy vs. Combination Therapies in Men with Congenital Hypogonadotropic Hypogonadism: A Systematic Review and Meta-Analysis.
Pozzi E, Ila V, Petrella F, et al.
The world journal of men's health 2025; (43(3)):552-562 doi:10.5534/wjmh.240095.
PMID: 39434392 - 13
Management of ovulation induction and intrauterine insemination in infertile patients with hypogonadotropic hypogonadism.
Huseyin K, Berk B, Tolga K, et al.
Journal of gynecology obstetrics and human reproduction 2019; (48(10)):833-838 doi:10.1016/j.jogoh.2019.03.027.
PMID: 30930300 - 14
Hypopituitarism.
Fleseriu M, Christ-Crain M, Langlois F, et al.
Lancet (London, England) 2024; (403(10444)):2632-2648 doi:10.1016/S0140-6736(24)00342-8.
PMID: 38735295 - 15
Reproductive endocrine phenotypes relating to CHD7 mutations in humans.
Balasubramanian R, Crowley WF
American journal of medical genetics. Part C, Seminars in medical genetics 2017; (175(4)):507-515 doi:10.1002/ajmg.c.31585.
PMID: 29152903
This page is for informational purposes only and does not constitute medical advice. Your endocrinologist and reproductive specialist can tailor hormone, bone, and fertility care to your or your child's needs.